Riboxx Pharmaceuticals, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and Accinov, a pharmaceutical establishment for experimental drug products, announced the successful industrial GMP manufacturing, including packaging and quality control of Riboxxim, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand. Manufacturing has been performed with the patented process Tenpora of Riboxx in full compliance with the EU GMP requirements, and with...